佛仁制药品牌怎么样 申请店铺

我要投票 佛仁制药在医疗器械行业中的票数:93 更新时间:2025-01-23
佛仁制药是哪个国家的品牌?「佛仁制药」是 甘肃佛仁制药科技有限公司 旗下著名品牌。该品牌发源于陇南市,由创始人曹明月在2004-03-29期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
佛仁制药怎么样

甘肃佛仁制药科技有限公司是在收购原甘肃武都制药厂的基础上重新组建的一家股份制企业,主要利用地方特色药材资源,从事中成药产品的生产经营,有40多年的生产历史。2010年1月再次通过了国家GMP认证,是药品生产国家GMP认证企业。具有“国药准字”批准文号的产品46个,其中14个品种是2009年国家新选定的国家基本药物。

公司座落于陇南市武都工业园区,占地面积为43亩,建筑面积为5800平方米,总投资为2745万元,形成固定资产投资1120万元。建有中药材前处理、中药提取、综合制剂和动力维修四个车间,拥有片剂、丸剂、颗粒剂、散剂四条生产线。再建的生产线有胶囊剂、糖浆剂、酊剂、煎膏剂、流浸膏剂,以及中药饮片车间。

安装有35000m3/h风量的空气净化装置,总体净化级别达到了10万级,高出了国家要求。设有新产品开发研究所和产品检验质保中心。公司整体生产设备齐全,检验仪器齐全。年具有生产丸剂1000吨(大蜜丸500吨、水丸320吨、浓缩丸180吨),片剂4亿片、颗粒剂2000万袋、散剂300万袋的生产能力。

企业组织机构健全,人员结构合理。现有职工96人,各类专业技术人员占员工总数的28%。企业通过不断的技术改造,采取新工艺,购置新设备,在努力提高产品质量的同时,以务实诚信为经营理念,企业品牌的建设和产品影响力已初具规模,公司为了更及时快捷的给客户提供服务,特在郑州设立全国营销中心,面向全国进行推广,产品遍及全国各地30多个省市。2013年实现销售收入3000多万元,上缴税金200多万元,预计2014年销售收入可达近5000万元,利税在420万元以上。

甘肃佛仁制药科技有限公司无论是产品的技术优势还是市场优势,都具有广阔的发展前景。我们会把可持续发展战略相关产业链上的工作和包括环境保护在内的各项工作做的更好,为推动地方中药材持续发展,带动药农脱贫致富,解决下岗职工再就业,为人类社会和经济的发展做出应有的贡献。


Gansu Furen pharmaceutical science and Technology Co., Ltd. is a joint-stock enterprise re established on the basis of the acquisition of the former Gansu Wudu pharmaceutical factory. It mainly uses local characteristic medicinal materials resources to engage in the production and operation of Chinese patent medicine products, with a production history of more than 40 years. In January 2010, it passed the national GMP certification again, and is a national GMP certification enterprise for drug production. There are 46 products with the approval number of "Guoyao Zhunzi", 14 of which are national essential drugs newly selected by the state in 2009. The company is located in Wudu Industrial Park, Longnan City, covering an area of 43 mu, a building area of 5800 square meters, with a total investment of 27.45 million yuan, forming a fixed asset investment of 11.2 million yuan. There are four workshops for Chinese medicine pretreatment, Chinese medicine extraction, comprehensive preparation and power maintenance, and four production lines for tablets, pills, granules and powders. The newly built production lines include capsule, syrup, tincture, decocting agent, liquid extract, and herbal pieces workshop. The air purification device with 35000m3 / h air volume is installed, and the overall purification level has reached 100000, which is higher than the national requirements. There are new product development research institute and product inspection and Quality Assurance Center. The company has complete production equipment and inspection instruments. The annual production capacity is 1000 tons of pills (500 tons of honey pills, 320 tons of water pills and 180 tons of concentrated pills), 400 million tablets, 20 million bags of granules and 3 million bags of powder. The organizational structure of the enterprise is sound and the personnel structure is reasonable. At present, there are 96 employees, 28% of which are professional technicians. Through continuous technological transformation, adopting new technology and purchasing new equipment, while striving to improve the quality of products, the company has established a national marketing center in Zhengzhou to provide services to customers in a more timely and efficient manner, with pragmatic and honest business philosophy, and its brand building and product influence has taken shape. Its products are spread all over the country Multiple provinces and cities. In 2013, the company realized sales revenue of more than 30 million yuan and paid taxes of more than 2 million yuan. It is estimated that in 2014, the sales revenue will reach nearly 50 million yuan and the profit and tax will be more than 4.2 million yuan. Gansu Furen pharmaceutical science and Technology Co., Ltd. has broad prospects for development, both in terms of technical advantages and market advantages. We will do a better job in the industry chain related to the sustainable development strategy and in various works including environmental protection, in order to promote the sustainable development of local traditional Chinese medicine, drive pharmaceutical farmers out of poverty and become rich, solve the problem of reemployment of laid-off workers, and make due contributions to the development of human society and economy.

本文链接: https://brand.waitui.com/559930f52.html 联系电话:09398890269

千城特选小程序码

7×24h 快讯

千红制药:预计2024年归母净利润3.2亿元-3.8亿元,同比增长75.96%-108.95%

36氪获悉,千红制药发布2024年业绩预告。报告显示,预计2024年归母净利润3.2亿元-3.8亿元,同比增长75.96%-108.95%。2024年度销售收入虽因药品价格下降而下降,但主要产品销量均保持增长且毛利率较上年同期持续提升,由此归母净利润实现了同比较大幅度提升。

2小时前

飞荣达:子公司拟3.8亿元收购江苏中煜100%股权

36氪获悉,飞荣达公告,公司全资子公司江苏飞荣达拟收购江苏中煜橡塑科技有限公司(简称“江苏中煜”)100%股权,交易价格为3.8亿元。标的公司是一家以高端橡胶密封件及新能源汽车橡胶制品生产销售为一体的制造型企业,并拥有专业的橡胶材料研发的技术团队。本次收购将丰富公司在新能源领域的产品矩阵,增强公司电磁屏蔽及热管理解决方案的综合能力,有效实现资源整合及业务协同,有利于提升公司综合竞争力及市场份额。

2小时前

中航电测:拟变更证券简称为“中航成飞”

36氪获悉,中航电测公告,公司于2025年1月22日召开2025年第一次临时股东大会,审议通过了《关于变更公司名称、证券简称、经营范围及修订的议案》《关于变更公司证券代码的议案》。公司拟将证券简称由“中航电测”变更为“中航成飞”,英文简称由“ZEMIC”变更为“AVIC CAC”。本次变更后的证券简称及证券代码拟启用日期待定,以深圳证券交易所最终核准的日期为准。公司特别提示广大投资者充分知晓。

2小时前

支付宝:“碰一下钱被隔空盗刷”系摆拍,部分造谣者已被惩处

36氪获悉,据支付宝安全中心微博,近期,部分自媒体为吸引眼球和流量,发布摆拍虚假视频,捏造“使用支付宝碰一下钱被隔空盗刷”等不实内容。经公安机关依法办案,部分造谣者已受到应有的惩处。

2小时前

欧盟据悉提议成立专注于AI等战略技术的高级研究机构

据报道,欧盟将提议仿照美国政府建立一个高级研究项目机构,投资战略技术。欧盟还将呼吁为人工智能建设新的超级计算基础设施。据知情人士和文件消息,这些计划已被纳入欧盟将于1月底发布的新战略草案中,同时发布的还有关于削减监管、改善资金获取、降低能源成本和减轻与关键材料相关的依赖性的建议。(界面)

2小时前

本页详细列出关于Medtronic美敦力的品牌信息,含品牌所属公司介绍,Medtronic美敦力所处行业的品牌地位及优势。
咨询